CC
RETA

Carlson Capital’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Carlson Capital’s Portfolio RETA Stock Details RETA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-9,700
Closed -$967K – 210
2021
Q1 		$967K Buy
+9,700
New +$1.13M 0.04% 162

Other funds holding RETA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CI
CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return

Carlson Capital's RETA Position: Q2 2021 in Review

Carlson Capital sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q2 2021, closing a stake of 9,700 shares — an estimated $967K sold.

Carlson Capital first reported a position in RETA in Q1 2021 and held it in 1 quarter. The position peaked at $967K in Q1 2021. 194 funds tracked by Wall St. Rank hold RETA as of Q2 2021.

  • Carlson Capital reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q2 2021 after selling out during the quarter.
  • Carlson Capital sold 9,700 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q2 2021, an estimated $967K.
  • Carlson Capital first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2021 and held it in 1 quarter.
  • Carlson Capital's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $967K in Q1 2021.
  • 194 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q2 2021.

Based on Carlson Capital's 13F filing for Q2 2021, filed 13 Aug 2021.